




Address for correspondence: Aleksander Kania, Division of Pulmonary Diseases, Dept. of Internal Medicine, Jagiellonian University School of Medicine, 8 Skawińska Str.,
31–066 Kraków, ph.: (012) 430 52 66; fax: (012) 430 52 03, e-mail: ollekk@interia.pl
Received: 10.03.2008
Copyright © 2008 Via Medica
ISSN 0867–7077
Bożena Ziółkowska-Graca1, Aleksander Kania1, Grażyna Zwolińska2,
Ewa Niżankowska-Mogilnicka1
1Division of Pulmonary Diseases, Department of Internal Medicine, Jagiellonian University School of Medicine, Krakow, Poland
Head of unit: Prof. Ewa Niżankowska-Mogilnicka
2Department of Neurology, Jagiellonian University College of Medicine, Krakow, Poland
Head of unit: Prof. Andrzej Szczudlik
Adult form of Pompe disease
Abstract
Pompe disease (glycogen-storage disease type II) is an autosomal recessive disorder caused by a deficiency of lysosomal
acid a-glucosidase (GAA), leading to the accumulation of glycogen in the lysosomes primarily in muscle cells. In the adult
form of the disease, proximal muscle weakness is noted and muscle volume is decreased. The infantile form is usually fatal.
In the adult form of the disease the prognosis is relatively good. Muscle weakness may, however, interfere with normal daily
activities, and respiratory insufficiency may be associated with obstructive sleep apnea. Death usually results from respira-
tory failure. Effective specific treatment is not available. Enzyme replacement therapy with recombinant human GAA
(rh-GAA) still remains a research area.
We report the case of a 24-year-old student admitted to the Department of Pulmonary Diseases because of severe respira-
tory insufficiency. Clinical symptoms such as dyspnea, muscular weakness and increased daytime sleepiness had been
progressing for 2 years. Clinical examination and increased blood levels of CK suggested muscle pathology. Histopathologi-
cal analysis of muscle biopsy, performed under electron microscope, confirmed the presence of vacuoles containing
glycogen. Specific enzymatic activity of a-glucosidase was analyzed confirming Pompe disease.
The only effective method to treat respiratory insufficiency was bi-level positive pressure ventilation. Respiratory rehabilita-
tion was instituted and is still being continued by the patient at home. A high-protein, low-sugar diet was proposed for the
patient. Because of poliglobulia, low molecular weight heparin was prescribed. The patient is eligible for experimental
replacement therapy with rh-GAA.
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Case study
A 24-year-old student was admitted to the
Department of Pulmonary Disease from the Depart-
ment of Neurological Disease. His condition was
described as very serious because of rest dyspnea,
considerable muscular weakness, increased day-
time sleepiness and significant bradyphrenia.
The physical examination confirmed conside-
rable rest dyspnea which was slightly decreased
in a sitting position, fatigue when attempting to
speak at length, sleepiness and bradyphrenia.
Cyanosis of the lips and mucosae, lacrimation
and congestion of the eyes, and substantial peri-
pheral oedema were observed. He had an enlarged
liver, heart rate increased to 100/min and increased
second heart sound above the pulmonary valve.
The patient had had limited motor skills since child-
hood. At the age of 10 a routine check-up reve-
aled increased values of both liver enzymes and
creatine kinase in his blood. Subsequent tests ex-
cluded viral hepatitis but no further diagnostics
were conducted. The patient was under periodic
observation. From the age of 22 a substantial dete-
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positive airway pressure) proved sufficient to nor-
malize gasometric parameters (pO2 60 mm Hg,
pCO2 48 mm Hg, pH 7.39). Intensive respiratory
rehabilitation was instituted and is still being con-
tinued by the patient at home. A low-sugar, high-
-protein diet was recommended as standard proce-
dure. Because of poliglobulia, low molecular we-
ight heparin was prescribed. The patient’s condi-
tion improved gradually; respiratory insufficien-
cy receded completely and the parameters were
normal. Subsequent laboratory tests after 2 mon-
ths showed normalization of blood cell count and
decreased CK level to 1271 U/l. Echocardiography
control test did not indicate raised pressure in the
pulmonary artery. Daytime sleepiness receded. The
patient felt fine; he was able to make more and
more effort and continued his studies. He repor-
ted a considerable improvement in the quality of
life. He became a member of an international sup-
port group for people suffering from Pompe dise-
ase and was qualified for experimental therapy
with recombined enzyme of a-glucosidase rhGAA
(drug: Myozyme).
Discussion
Pompe disease (type II glycogenosis; GSD II)
is a glycogen storage disease. It is a rare genetic
autosomal recessive disorder. It is a deficiency of
lysosomal acid a-1.4-glucosidase (acid maltase) —
the enzyme responsible for eliminating excess gly-
cogen in lysosomal vacuoles of cells. The result is
the accumulation of glycogen in the body, espe-
cially in liver cells, skeletal muscles, the heart, glia
cells, nucleus of the brain trunk and anterior horn
of the spinal cord. This is the only glycogenosis in
which glycogen is accumulated in cell lysosomes
and not cytoplasm.
The disorder is very rare. It was first descri-
bed in 1932 by a Dutch pathologist J.C. Pompe. It
is unknown precisely how many people suffer from
it. It occurs in approximately 1 out of 40 000 births.
Less than 200 000 people in the United States and
no more than 5000–10 000 in Europe are affected.
Although it occurs in people of all races, it affects
African Americans more often (1/14 000 births)
than Caucasians (1/60 000 adults and 1/100 000
children).
Clinical picture
The disease has many phenotypes. Myopathy
occurs in each phenotype, but they differ with re-
gard to the age when symptoms appear, the degree
to which organs are affected by the pathogenic
process, and how serious the clinical symptoms
rioration of the patient’s health had been observed.
Muscular weakness of the lower, and later the up-
per, limbs was noted. At that time peripheral oede-
ma of lower limbs and cyanosis of the lips and mu-
cosae also appeared. After a few months the pa-
tient’s condition further deteriorated. He compla-
ined of fatigue, daytime sleepiness, problems with
concentration, and bradyphrenia. Peripheral oede-
ma aggravated, his abdominal circumference incre-
ased, and central cyanosis, lacrimation and serio-
us conjunctival reddening were observed.
During hospitalization, laboratory tests reve-
aled poliglobulia: Hb 17.8 g/dl, HCT 57.2%, RBC
7.5 mln/µl, and abnormal values of enzymes:
AspAT 240 U/l, ALAT 260 U/l, CK 2680 U/l, CK-
-MB 71 U/l. Gasometric examination of arterial blo-
od showed total respiratory failure: pH 7.25, pO2
47 mm Hg, and pCO2 70 mm Hg. No abnormalities
were found in thorax X-ray or high resolution com-
puter tomography. EKG examination showed sinus
rhythm 100/min, normal electrical axis, negative
T waves in leads III and aVL and deep S waves in
leads V1–V3. Echocardiography revealed increased
right ventricle of the heart with average pressure
in pulmonary artery app. 70 mm Hg, paradoxical
ventricular septal movement and widened trunk
of the pulmonary artery (3.74 cm).
Pathology of the respiratory and circulatory
systems was eliminated as the source of respirato-
ry failure, and myogenic background was suspec-
ted. Histological examination of a deltoid muscle
biopsy showed the presence of vacuoles, suggesting
the accumulation of glycogen, which is typical of
Pompe disease. The diagnosis was fully confirmed
upon determination of the ratio of specific lysoso-
mal a-glucosidase of leukocytes in a dry drop of
blood with pH 3.8 with and without the presence
of the inhibitor. This activity was profoundly de-
creased (0.08, with control values ranging from
0.29 to 0.49). Moreover, the ratio of enzymatic ac-
tivity with pH 4.5–6.0 was only 0.01, while for a
healthy individual it exceeds 0.37. This result fur-
ther confirmed the diagnosis of Pompe disease. The
activity of lysosomal a-glucosidase of leukocytes
was analyzed in the Metabolic Laboratory in the
Department of Genetics of the Institute of Psychia-
try and Neurology.
Treatment
Due to the patient’s respiratory failure, bi-le-
vel positive pressure ventilation was used in his
treatment. The algorithm S (spontaneous) and
a pressure of 12 mbar for IPAP (inspiratory positive
airway pressure) and 6 mbar for EPAP (expiratory
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are. The most severe form of the disease is infantile
form, which is manifested by decreased muscle tone,
tongue hypertrophy, hepatomegaly, and congestive
heart failure caused by hypertrophic cardiomyopa-
thy. Death usually occurs before the second birth-
day as a consequence of cardiorespiratory failure or
aspiration pneumonia. The activity of a-glucosidase
enzyme in these patients is less than 1% of the norm.
The juvenile form is mainly characterized by
slowly progressing symptoms in skeletal muscles.
Typical symptoms include: retarded stages of mo-
tor development, limited ability to walk, difficulty
in swallowing, weakness of proximal muscles in the
extremities and respiratory insufficiency due to re-
spiratory muscles being affected by pathogenic pro-
cesses. Death usually occurs before the patient is
20 years old. The activity of a-glucosidase enzyme
in these patients is less than 10% of the norm.
The adult form of Pompe disease is manifested
by slowly progressing proximal muscle weakness
including respiratory muscles. The upper limb gir-
dle muscles, prevertebral muscles and diaphragm
are affected the most. The primary symptom may
be respiratory insufficiency, and as a result: sleepi-
ness, morning headaches, proper respiration only
in standing position, effort dyspnea, and symptoms
of obstructive sleep apnea. Other noted symptoms
include enlarged liver and, less often, tongue
hypertrophy which interferes with swallowing
and mastication of food.
Laboratory tests show raised concentrations of
creatine kinase, aspartate transaminase and lactate
dehydrogenase in serum. In electromyographic in-
vestigation, features of myopathy with hyperexci-
tability of muscle fibres and pseudotonic impul-
ses are often visible. The activity of a-glucosidase
enzyme in these patients is less than 40% of the norm.
A lack of activity of a-glucosidase enzyme or
its lower level in a biopsy sample from the affected
area allows diagnosis of the disorder. Most often
a sample of skin or muscle is collected. Additionally,
the presence of vacuoles which positively stain to-
wards glycogen in bioptate cells is noted.
Treatment
Until recently no effective method to treat Pom-
pe disease existed. At present, enzymatic replace-
ment is the most important therapy. The research
on this method, although it has been conducted for
some time, has entered an advanced stage recently.
Attempts to acquire recombined a-glucosidase iso-
lated from transgenic rabbit’s milk have been
successful. The alternative for this method is to
acquire the enzyme from Chinese hamster ovary
cells after prior introduction of a-glucosidase.
The therapeutic action of this substance is
based on the assumption that the enzyme, having
been administered intravenously, is intercepted by
the cells of skeletal muscles and the heart through
a receptor mechanism linked with mannose-6-pho-
sphorate receptor. In this way the concentration of
the enzyme within the cells should increase.
In recent years numerous clinical tests have
been conducted which aim at assessing the effec-
tiveness of the enzyme. The tests have mainly been
carried out on neonates and infants up to the age
of 6 months suffering from Pompe disease. The
infantile form of the disease is considerably more
frequent and more severe than that found in older
children and adults. After a few months of treat-
ment a substantial improvement in the children’s
clinical state was noted. The observations that were
made included improvement of physical strength,
which was assessed based on the children’s phy-
sical development, as well as a significant change
in the microscope picture of the examined muscle
tissue (less intensive staining by PAS method to-
wards the presence of glycogen). Cardiological
changes have also been monitored by heart echo-
graphy examinations. A decrease in left-ventricu-
lar mass index to a value which approximates the
norm has been observed in all treated children,
although the initial value exceeded the standard
almost by a factor of three.
In medical references only one study is ava-
ilable discussing the results of research done on
adult patients. Three patients aged 11, 16 and 32
were administered the enzyme intravenously in
weekly doses of 10–20 mg/kg. Significantly impro-
ved muscular strength and increased respiratory
efficiency parameters were observed in all 3 pa-
tients. With larger doses it was possible to achieve
a sizable increase of the enzyme activity in mus-
cles. The best results were noted in the youngest
patient, who was least affected by the disease. The
indications of progress in the other 2 patients were
primarily disability reduction and cardiorespira-
tory stabilization. It was observed that the impro-
vement was greater in groups of muscles that were
used more often. The administered preparation
usually caused no side effects that would require
further treatment.
In 2006 the Federal Drug Administration ap-
proved the clinical use of a-glucosidase under the
trade name Myozyme, as the first and only drug to
be used in Pompe disease replacement therapy.
For treating milder forms of the disorder,
which occur in youths and adults, following a low-
-sugar, high-protein diet is quite significant. Phy-
sical rehabilitation is vital in the treatment of all
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types of the disease. If respiratory failure or sleep ap-
nea occur, it is necessary to apply non-invasive me-
chanical ventilation with continuous positive pressure
in the respiratory tract, preferably by bi-level method.
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